- Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
- Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain
- Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
- Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
- Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
- Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
- Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
- Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
- Cybin Announces Additional Adelia Milestone Achievement
- Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
Cybin Inc (CYBN:ASQ) closed at 0.4248, 8.84% above its 52-week low of 0.3903, set on May 13, 2022.
0.3903May 13 20223.38Aug 02 2021
Markit short selling activity
|Market cap||102.46m CAD|
|EPS (TTM)||-0.4375 |
Data delayed at least 15 minutes, as of May 16 2022 21:10 BST.